JODY BECK: Open Payments
NPI 1346727815 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,080 in 45 payments from 26 companies in 2025. Trend: 2023 $147 · 2024 $609 · 2025 $1,080
Food & beverage: $1,080
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $252 |
| Merck Sharp & Dohme LLC | 4 | $109 |
| ABBVIE INC. | 3 | $72 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| Janssen Biotech, Inc. | 2 | $56 |
| AstraZeneca Pharmaceuticals LP | 2 | $51 |
| BeiGene USA, Inc. | 2 | $46 |
| GlaxoSmithKline, LLC. | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| PharmaEssentia USA Corporation | 1 | $32 |
Products named: KISQALI, KEYTRUDA, LIBTAYO, Fabhalta, Venclexta, JEMPERLI, SCEMBLIX, ELAHERE.
Industry payments across DC — which companies pay providers there.
